SESSION TITLE: Airways 4
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM
PURPOSE: Omalizumab is indicated for treatment of patients with severe allergic asthma and well defined omalizumab efficacy in this patients, but there are no study regarding effectiveness of omalizumab in patients with Asthma-COPD Overlap Syndrome (ACOS) . ACOS is a syndrome characterized by reversible but persistant airflow limitation which has some features of both asthma and COPD. Frequent and severe exacerbations and related hospitalization are common in ACOS. We aimed to describe our experience with the clinical and functional effectiveness of the omalizumab treatment in patients with ACOS.